Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme.

"Conflict of Interest SS has received consulting fees from AbbVie, Amgen, Arena, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Dr Falk Pharma, Eli Lilly, Ferring, Fresenius, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, I-MAB Biopharma, Janssen, Merck, Novartis/Sandoz, Pfizer Inc, Protagonist, Takeda, and Theravance. DTR has received consulting fees from AbbVie, AltruBio, Arena, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corp/Syneos, Connect BioPharma, Eli Lilly, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, InDex Pharmaceuticals, Iterative Scopes, Janssen, Pfizer Inc, Prometheus Biosciences, Reistone, Takeda, and Techlab; and research support from Takeda. SCN has received research support from AbbVie, Ferring, and Olympus; speaker fees from AbbVie, Ferring, Janssen, Menarini, Pfizer Inc, Takeda, and Tillotts; and holds a directorship with Microbiota I-Center. LP-B has received personal fees from AbbVie, Alimentiv, Allergan, Amgen, Arena, Biogen, Bristol-Myers Squibb, Celgene, Celltrion, Eli Lilly, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead Sciences, Gossamer Bio, InDex Pharmaceuticals, Inotrem, Janssen, MSD, Mylan, Norgine, ONO Pharma, OSE Immunotherapeutics, Pandion Therapeutics, Pfizer Inc, Roche, Samsung Bioepis, Sandoz, Takeda, Theravance, Thermo Fisher, Tillotts, Viatris, and Vifor Pharma; research support from AbbVie, Fresenius Kabi, MSD, and Takeda; and holds stock options for CTMA. SD has received consulting fees from AbbVie, Allergan, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Gilead Sciences, Hospira, Janssen, Johnson & Johnson, MSD, Mundipharma, Pfizer Inc, Roche, Sandoz, Takeda, TiGenix, UCB, and Vifor Pharma. IM, XG, CS, KKK, YC, and AY are employees and shareholders of Pfizer Inc. HJ is a former employee of Syneos Health, which was a paid contractor to Pfizer Inc in connection with the development of this manuscript and related statistical analysis. WR has received research support from AbbVie, Janssen, MSD, Sandoz, Sanofi, and Takeda; lecture fees from AbbVie, Celltrion, Dr Falk Pharma, Ferring, Galapagos, Janssen, MSD, Pfizer Inc, Pharmacosmos, Roche, Shire, Takeda, and Therakos; consulting fees from AbbVie, Amgen, AM Pharma, AOP Orphan, Arena, Astellas, AstraZeneca, Bioclinica, Boehringer Ingelheim, Bristol-Myers Squibb, Calyx, Celgene, Cellerix, Dr Falk Pharma, Eli Lilly, Ferring, Galapagos, Gatehouse Bio Inc, Genentech, Gilead Sciences, Grünenthal, ICON, InDex Pharmaceuticals, iNova, Janssen, Landos Biopharma, Medahead, MedImmune, Microbiotica, Millennium, Mitsubishi Tanabe Pharma, MSD, Novartis, OMass, Otsuka, Parexel, Periconsulting, Pfizer Inc, Pharmacosmos, Protagonist, Provention, Quell Therapeutics, Sandoz, Seres Therapeutics, SetPoint Medical, Sigmoid, Sublimity, Takeda, Teva Pharma, Therakos, Theravance, and Zealand; and advisory board fees from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Galapagos, Janssen, Mitsubishi Tanabe Pharma Corporation, MSD, Pfizer Inc, Pharmacosmos, Sandoz, and Takeda. MCD has received consulting fees from AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead Sciences, Janssen, Pfizer Inc, Prometheus Laboratories, Takeda, and UCB."

"Funding This work was supported by Pfizer. This study was sponsored by Pfizer."